Principal Investigator(s): Alfonso Clavijo, DVM, Ph.D.
The goal of this project is to generate high-quality, monoclonal antibodies to support Foot and Mouth Disease (FMD) diagnosis and research. Monoclonal antibodies (mAbs) are a necessary component for many assays, including ones that are currently used and ones in development. This project will deliver novel monoclonal antibodies, including pan-viral reagents for use across all seven FMD virus (FMDv) serotypes.
Outcomes and impacts
This program produced critical reagents (recombinant proteins, peptides, and mAbs) required for FMDv diagnostic test development and pathogenicity, and vaccine research. The reagents will include FMDv recombinant proteins able to be produced in different protein expression systems, pan-reactive peptides, and mAbs with different specificities enabling diverse applications as needed. Successful production of these mAbs will enable diverse applications such as diagnostic tests and products enabling vaccine development including: in vitro cell-based FMD vaccine potency release assays, Western blots, enzyme linked immunosorbent assays (ELISA), and immunoprecipitation assays. In addition, this project will also provide highly valuable validation data for bioinformatics approaches for the identification of highly cross-reactive epitopes in the structural proteins of FMDv.